Scalper1 News
Drug stocks took a pounding in the third quarter, but the leading drug companies’ pipelines have kept flowing with potentially blockbuster new drugs. Here are three key products — from Merck, Shire and Gilead Sciences — expected to be approved by the FDA in the next month or so: By Friday, Merck (MRK) is expecting to hear whether the agency will approve Keytruda for advanced non-small-cell lung cancer. Keytruda has already been on the market for a Scalper1 News
Scalper1 News